Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.59 |
| ▸ | NPC1L1 | Q9UHC9 | 8/20 | 0.56 |
| ▸ | CCR5 | P51681 | 2/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.43 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7845129 | 0.85 | NPC1L1 (0.58) | NPC1L1CCR5USP30GPR119ATM | |
| SCHEMBL17140692 | 0.85 | NPC1L1 (0.58) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318404 | 0.85 | NPC1L1 (0.53) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318405 | 0.85 | NPC1L1 (0.53) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL318942 | 0.85 | NPC1L1 (0.53) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL20187075 | 0.83 | DDR1 (0.62) | NPC1L1CCR5DDR1 | |
| SCHEMBL12315539 | 0.82 | MC4R (0.49) | OPRM1OPRD1OPRK1OPRL1NPC1L1 | |
| SCHEMBL319067 | 0.82 | NPC1L1 (0.55) | OPRD1OPRK1NPC1L1CCR5USP30 | |
| SCHEMBL1855447 | 0.82 | NPC1L1 (0.70) | OPRM1OPRK1NPC1L1DDR1BDKRB2 | |
| SCHEMBL5563023 | 0.81 | NPC1L1 (0.64) | OPRM1OPRD1OPRK1OPRL1NPC1L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263608-B2 | Melanocortin receptor-specific spiro-piperidine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | MC1R, MC5R, MC3R | OPRM1 59/4885OPRD1 21/4885OPRK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.